

Patent Claims

1. An anti-CD20 antibody selected from a type I anti-CD20 antibody or obinutuzumab for use in the treatment of CD20 expressing cancer in combination with 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one or a salt thereof.
5
2. The antibody for use according to claim 1, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.
3. The antibody for use according to claim 1 or 2, characterized in that said type I anti-CD20 antibody is rituximab.
- 10 4. The antibody for use according to any one of claims 1 to 3, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation enhancing the effects of such agents are to be administered.
- 15 5. A pharmaceutical composition comprising a combination of an anti-CD20 antibody selected from a type I anti-CD20 antibody or obinutuzumab, and 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-